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The clinical trial EMPA-REG OUTCOME 
investigated the efficacy of empagliflozin – a 
specific and reversible inhibitor of the sodi-
um-glucose co-transporter type 2 (SGLT2) 
– in reducing the incidence of cardiovascu-
lar events and mortality in a cohort of 7,020 
patients with T2D and a previous history 
of established cardiovascular disease [4,5]. 
IntroductIon and objectIve
Type 2 diabetes (T2D) – the most common 
form of diabetes, with a prevalence of about 
90% of cases – is identified as an important 
risk factor for cardiovascular events [1,2]. 
Cardiovascular diseases are also the leading 
cause of death in diabetic subjects worldwide, 
amounting to about 50% in T2D patients [3].
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abstract
INTRODUCTION: The EMPA-REG OUTCOME trial demonstrated the efficacy of empagliflozin in the treatment of type 
2 diabetes (T2D) with a previous history of cardiovascular (CV) disease. The drug is currently reimbursed for T2D Italian 
patients, but the reduction of CV mortality and morbidity shown in the trial opens a new treatment perspective in those 
patients with associated high CV risk.
OBJECTIVE: Cost-effectiveness analysis of empagliflozin for the treatment of T2D patients with a previous history of CV 
disease, from the Italian National Health Service (NHS) perspective.
METHODS: The analysis was performed with an individual simulation model, which can predict the time to CV events 
or death through a set of time-dependent regressions estimated on the patient-level data of the EMPA-REG OUTCOME 
trial. This design allows the direct simulation of long-term outcomes and costs without the need for surrogate endpoints. 
The model was adapted to the Italian setting, considering local epidemiological data, baseline quality of life (QoL) utility, 
background mortality and unit costs from current prices and tariffs. The cost perspective was that of the Italian NHS and 
the horizon of the simulation was lifetime. Costs and benefits were discounted at a 3.5% rate.
RESULTS: Base case results were estimated on a cohort of 5,000 patients, which ensured the convergence of the simula-
tion. Patients treated with empagliflozin in add-on to the standard of care (SoC) lived on the average 13.8 undiscounted 
years as compared to 11.8 years of patients on SoC alone. The gain in discounted quality-adjusted life years (QALYs) was 
1.0, due to improved survival and QoL linked to the reduced incidence of CV events and CV mortality. The incremental 
cost-effectiveness ratio (ICER) was 4,811 €/QALY, well below the commonly applied threshold of 30,000-50,000 €/QALY.
CONCLUSION: Empagliflozin in add-on to the SoC is a highly cost-effective strategy for the treatment of T2D patients 
with known CV disease in the Italian setting. 
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lation model, to directly integrate the statis-
tical analyses developed on the patient data 
of the EMPA-REG OUTCOME study and 
to perform the pharmacoeconomic compari-
son between empagliflozin and the Standard 
of Care (SoC) therapy in subjects with T2D 
and established cardiovascular disease [7,8]. 
As detailed in the following paragraphs, the 
model allows to extrapolate the risk func-
tions of cardiovascular and renal events di-
rectly from the EMPA-REG OUTCOME 
data, without the need to refer to surrogate 
outcomes. The economic model was adapted 
in order to carry out an analysis which is ad-
herent with the Italian clinical setting. The 
cost-effectiveness analysis was conducted 
in the perspective of the Italian NHS, with 
a time horizon corresponding to the entire 
life of patients (lifetime horizon). Costs and 
benefits were discounted at the annual rate 
of 3.5%.
Model design
The model is based on the patient-level simu-
lation of the time to the occurrence of each 
of the nine possible cardiovascular or renal 
events, defined in accordance with the EM-
PA-REG OUTCOME study protocol [4,9]:
 - Non-fatal myocardial infarction;
 - Non-fatal ischemic stroke;
 - Hospitalization due to heart failure;
 - Transient ischemic attack;
 - Coronary revascularization;
 - Death from cardiovascular causes;
 - New onset of macroalbuminuria;
 - Kidney injury (doubling of serum creati-
nine level and eGFR = 45 ml/min/1.73m2);
 - The beginning of renal-replacement ther-
apy.
A set of parametric functions embedded in 
the model – derived on the basis of multivari-
ate and time-dependent regressions of patient 
data from the EMPA-REG OUTCOME study 
– allows to estimate the time to events, ac-
cording to baseline characteristics and the oc-
currence of previous events. More details on 
the derivation of the parametric functions is 
reported in the Appendix A. The simulation 
flow is schematically represented in Figure 
1. Each simulated patient is created based 
on the distribution of baseline characteris-
tics and sent to the two comparator’s arms, 
i.e. treatment with empagliflozin + SoC and 
SoC alone. At the beginning of the simula-
tion, the time to the first event is determined. 
After this event, the quantities representing 
the outcomes (survival, quality-adjusted life 
years –QALY, and costs) are updated. In ad-
dition, risk functions are updated to take into 
account the event occurred. At this point, the 
simulation goes to the next event and pro-
Patients were randomized to receive em-
pagliflozin or placebo in addition to their 
standard therapy. The primary endpoint of 
the study – defined as a composite endpoint 
of death from cardiovascular causes, (non-
fatal) myocardial infarction or stroke – was 
achieved over a median follow-up of 3.1 
years, with an incidence of 10.5% in the em-
pagliflozin group and 12.1% in the placebo 
group (hazard ratio = 0.86; CI95%: 0.74-
0.99; p = 0.04 for superiority). Among the 
secondary endpoints, cardiovascular mortal-
ity was reduced by 38%, mortality for any 
cause was reduced by 32%, hospitalizations 
for heart failure were reduced by 35%, and 
kidney damage progression was reduced by 
39% [4,5].
Empagliflozin is currently authorized and 
reimbursed by the Italian National Health 
Service (NHS) for use in T2D patients; how-
ever, the clinical evidence derived from the 
EMPA-REG OUTCOME study opens a new 
treatment perspective in the patient at high 
risk due to established cardiovascular dis-
ease. In this sense, it is important to explore 
its effects and consequences also in the eco-
nomic context. In fact, a comprehensive as-
sessment of a health technology – besides the 
evaluation of its clinical efficacy and safety 
– should also include an assessment of its 
economic effectiveness and sustainability, 
with the aim of satisfying the need to ratio-
nalize the allocation and use of the available 
resources, by providing the healthcare deci-
sion-maker with objective evaluation criteria. 
In general, comprehensive economic evalua-
tions consist of two elements. The first type 
of analysis – usually carried out in the form 
of cost-effectiveness, or cost-utility, over a 
medium to long-term time horizon – aims at 
estimating the efficiency of the allocation of 
health resources for a certain technology. The 
second type, typically defined as a budget 
impact analysis, answers the most immediate 
and frequent question of the decision maker 
about short-term (1-3 years) financial sus-
tainability.
The economic assessment of empagliflozin in 
diabetic patients with established cardiovas-
cular disease was first addressed through an 
analysis of the second type [6]. The aim of 
this study is the cost-effectiveness evaluation 
of empagliflozin in addition to the standard 
of care therapy as compared to the standard 
of care alone in the perspective of the Italian 
NHS.
MaterIals and Methods
The cost-effectiveness analysis was conduct-
ed in MS Excel, with the support of a simu-
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simulated population
As described above, patients are individually 
simulated, with baseline characteristics de-
scribing the risk profile randomly extracted 
from statistical distributions. During the pro-
cess of adaptation of the model to the Italian 
clinical setting a series of targeted literature 
searches were conducted to identify all rele-
vant sources of input data. The baseline char-
acteristics of the cohort of patients enrolled 
in the EMPA-REG OUTCOME study were 
replaced with Italian epidemiological data, 
available in the literature on the population 
of diabetic patients with established cardio-
vascular disease (T2D + CV) or, as a second 
choice, on the total population of diabetic 
(T2D) subjects [11,12]. Where Italian data 
were unavailable, the data of the subpopula-
tion of the EMPA-REG OUTCOME study 
enrolled in Europe were considered (Table I).
 
EMPA-REG OUTCOME 
(Europe)
Italian data
Population 
(Italian data)
source
Age (mean ± SD) 63.9 ± 8.3 66.0 ± 9.0 T2D [11]
Female (%) 28.5 42.5 T2D + CV [11]
BMI ≥ 30 (%) 60.8 63.1 T2D [11]
HbA1c ≥ 8.5% (%) 31.6 23.7 T2D [11]
CV risk variables (%) 
BCV1 (previous stroke) 27.1 15.5 T2D + CV [11]
BCV2 (MI) 50.6 38.1 T2D + CV [11]
BCV3 (CABG) 20.4  n/a   
BCV4 (MCAD) 40.6 n/a   
BCV5 (SVCAD) 11.8 n/a   
BCV 6 (PAD) 23.4 n/a   
Renal risk variables (%)
eGFR 60-90 53.4  n/a   
eGFR < 60 21.8 23.8 T2D [12]
Table I. Baseline characteristics of the simulated population. Where available Italian epidemiological data on the population of diabetic 
patients with established cardiovascular disease (T2D + CV) or on the total population of diabetic (T2D) subjects were considered. 
Where Italian data were unavailable, the data of the subpopulation of the EMPA-REG OUTCOME study enrolled in Europe were 
considered
CABG = coronary artery bypass graft; CAD = coronary artery disease; MI = myocardial infarction; MCAD = multi vessel CAD; n/a = not available; 
SVCAD = single vessel CAD; PAD = peripheral arterial disease
ceeds in this way until the final event, repre-
sented by the death of the patient, after which 
the outcomes in terms of survival, QALY 
and cost are stored in the system. The risk 
of death is calculated for both cardiovascu-
lar causes (based on the EMPA-REG OUT-
COME data) and for all other causes, using 
the mortality tables of the Italian population 
[10]. The simulation is repeated for a large 
number of iterations, determined in such a 
way as to allow for the convergence of the 
system. This condition occurs for a num-
ber of iterations, beyond which the median 
values of the simulation results remain sub-
stantially stable. When all patients have been 
simulated in both treatment arms, the overall 
outcomes are calculated, in order to estimate 
the cost-effectiveness of empagliflozin com-
pared with SoC in subjects with T2D and es-
tablished cardiovascular disease.
Figure 1. Patient-level simulation flow
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daily dose, based on the respective summary 
of product characteristics (SPC), and the ex-
factory price or that from the transparency 
list for equivalent products [18,19]. In the 
case of treatments available on the market in 
various packages, the unit price was calcu-
lated by weighing the cost of the individual 
products according to their relevant market 
shares [20]. In order to calculate the daily 
cost of insulin in monotherapy or in combina-
tion with oral antidiabetic agents, an average 
requirement of 20 IU/day for basal insulin 
and 50 IU/day for basal-bolus regimens was 
assumed. The use of basal insulin was esti-
mated at 100% in the case of combinations 
with sulphonylureas, GLP-1 and DPP-4, at 
75% when associated with repaglinide, and 
at 38% in combination with metformin [17].
Based on the assumptions hereby defined, 
the cost of the standard treatment was 1.20 
€/day. In line with the EMPA-REG OUT-
COME study design, it was assumed that 
the treatment with empagliflozin was added 
to the standard treatment, resulting in a to-
tal cost for the empagliflozin + SoC arm of 
2.55 €/day. However, the assumption of em-
pagliflozin add-on is conservative in the per-
spective of the economic evaluation. In fact, 
it seems unlikely that in the clinical practice 
empagliflozin could simply be added with-
out a concomitant adjustment of the ongoing 
therapy for each patient. Consequently, in 
concomitance with the base case, an alterna-
tive scenario was considered in which, in line 
with the previous budget impact analysis [6], 
it was assumed that the adoption of empa-
gliflozin occurred as a replacement of an oral 
antidiabetic agent, except for patients under 
treatment with metformin, insulin and insulin 
associated with metformin. In this scenario, 
the cost of the drug in the empagliflozin + 
SoC arm was 1.86 €/day.
Hospitalization costs for cardiovascular and 
renal events (Table III) were derived from 
the Italian Hospital Tariff System for acute 
diseases, weighed for the relative hospital-
ization frequencies [21,22]. For cardiovascu-
lar death, it was assumed that – on average 
– only half of the cases are hospitalized. The 
cost of renal replacement therapy was esti-
mated at € 41,027, corresponding to the cost 
of kidney dialysis per patient per year [23]. 
Finally, it was assumed that, for the manage-
ment of macroalbuminuria and kidney injury, 
there is no need for hospitalization, but out-
patient services are sufficient.
sensitivity analysis and scenarios
Cost-effectiveness analysis results were es-
timated for the base case and for an explor-
atory scenario. The latter concerned the cost 
Event Cost (€) source Reference
Non-fatal myocardial 
infarction
3,897.89 DRG 121 – CV disorders with acute MI, CV complications, discharged alive
DRG 122 – CV disorders with acute MI, without CV complications, discharged alive
[21,22]
Non-fatal stroke 6,073.00 DRG 559 – Acute ischemic stroke with use of thrombolytic agent [21]
Heart failure 3,052.00 DRG 127 – Heart failure and shock [21]
Transient ischemic 
attack
2,543.00 DRG 524 – Transient ischemic attack [21]
Coronary 
revascularization
8,080.55 DRG 547 – Coronary bypass with cardiac catheter with major CV diagnosis
DRG 549 – Coronary bypass without cardiac catheter with major CV diagnosis
DGR 553 – Other vascular procedures with CV complications with major CV 
diagnosis
DRG 555 – Percutaneous CV procedures with major CV diagnosis
DRG 557 – Percutaneous CV procedures with drug-eluting stent with major CV 
diagnosis
[21,22]
Macroalbuminuria 22.26 1 Creatinine test (90.16.4 creatinine clearance)
1 Nephrological visit (89.7 GP visit)
[21]
Kidney injury1 42.92 1 Creatinine test (90.16.4 creatinine clearance)
1 Nephrological visit (89.7 GP visit)
1 Nutritional visit (89.7 GP visit)
[21]
Kidney failure2 41,027.00 Annual cost for dialysis [23]
Cardiovascular 
death
2,009.00 DRG 123 – CV disorders with acute MI (assumption: 50% of sudden deaths/ not 
hospitalized)
[21]
Table III. Hospitalization costs for cardiovascular and renal events
1 Doubling of serum creatinine level and eGFR = 45 ml/min/1.73m2
2 Beginning of renal-replacement therapy
CV = cardiovascular; GP = general practitioner; MI = myocardial infarction
Quality of life data
Input data on the quality of life of patients 
with T2D and established cardiovascular dis-
ease are used to weigh the simulated survival 
and obtain the estimate of the QALYs gained 
in each of the two treatment arms. The base 
case utility was determined starting from the 
reference standard for the Italian population 
[13], reduced by the specific utility decrease 
related to the chronic diabetic condition (UK 
data in the absence of available Italian data) 
[14]. Specific utility reductions were also 
considered for all cardiovascular and renal 
events (Table II). These were obtained from a 
British study that estimated them based on a 
cohort of diabetic patients [15,16].
Cost data
The cost-effectiveness analysis was carried 
out in the perspective of the Italian NHS, 
therefore only direct health costs were taken 
into account, with costing year 2017. More 
specifically, the costs related to drug acqui-
sition and the management of cardiovascular 
and renal events were considered. Costs for 
drug acquisition were assessed considering 
the mix of drugs that define the standard treat-
ment in subjects with T2D and established 
cardiovascular disease. This was estimated 
through the QuintilesIMS Patient Analyzer 
service, based on the quarterly collection of 
anonymous patient records among a panel of 
140 diabetologists [17].
The daily cost of the individual drugs was 
calculated by considering the recommended 
 Utility, mean (95%CI) sources
Base case utility diabetic population 0.874 [13,14]
Utility decrease related to events
Non-fatal myocardial infarction -0.047 (-0.057;-0.036) [15]
Non-fatal stroke -0.060 (-0.074;-0.046) [15]
Heart failure -0.050 (-0.064;-0.036) [15]
Transient ischemic attack -0.070 (-0.131;-0.008) [15]
Coronary revascularization -0.030 [16]
Macroalbuminuria -0.038 (-0.059;-0.016) [15]
Kidney injury1 -0.038 (-0.059;-0.016) [15]
Kidney failure2 -0.038 (-0.059;-0.016) [15]
Effect of multiple events (additive with respect to the application of 
individual decreases)
2 events 0.017 [15]
3 events 0.042 [15]
4 events 0.070 [15]
5 or more events 0.087 [15,16]
Table II. Utility considered in the cost-effectiveness analysis
1 Doubling of serum creatinine level and eGFR = 45 ml/min/1.73m2
2 Beginning of renal-replacement therapy
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model and the repeatability of the results. Pa-
tients in the treatment arm with empagliflozin 
as an add-on to the SoC (condition not reim-
bursed according to the current therapeutic 
plan) lived for an average of 13.8 years, com-
pared to the 11.8 of the patients in the stan-
dard treatment, with a mean life expectancy 
gain of 2.0 years (Table IV).
The increased survival is related to the lower 
incidence of cardiovascular and renal events, 
particularly cardiovascular mortality. Due 
to the combined effect of improved survival 
and lower incidence of events, empagliflozin 
provides patients with a mean increase of 1.0 
QALY (discounted, and corresponding to 24 
months of life years gained), given by the dif-
ference between 8.6 QALYs and 7.6 QALYs 
Empagliflozin + soC soC Increments
Life Years 
(undiscounted)
13.8 11.8 2.0
QALYs 8.6 7.6 1.0
Total costs (€) 15,679 10,971 4,708
 • Drug costs(€) 9,460 3,951 5,509
 • Event costs (€) 6,219 7,021 -802
ICER (€/QALY) 4,811
Table IV. Undiscounted (survival) and discounted (QALY and costs) results of the 
cost-effectiveness analysis (base case)
ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life year; 
SoC = standard of care
of the drug, exploring the potential impact of 
considering empagliflozin in substitution for 
other antidiabetic drugs, and not simply as an 
add-on. In this scenario, the pharmaceutical 
cost in the empagliflozin + SoC arm was 1.86 
€/day (as compared to 2.55 €/day in the base 
case).
In order to estimate the impact of the uncer-
tainty of data on the results of the analysis, 
a probabilistic sensitivity analysis (PSA) was 
conducted, in which all the parameters of the 
model assume a probabilistic value distrib-
uted over their uncertainty range. The latter 
was assumed to be equal to CI95%, where 
this was reported in the original sources. 
For derivative parameters or parameters for 
which uncertainty information was not avail-
able, a conventional standard deviation value 
of ± 10% of the central value was considered. 
The Beta distribution was used for param-
eters constrained in the range (0-1) such as 
probabilities and utilities. The Gamma distri-
bution was used for all other parameters. The 
parameters of regression functions predicting 
the time to events were varied based on their 
variance-covariance matrix, using the Cho-
lesky decomposition method.
results
The base case simulation was carried out for 
a cohort of 5,000 patients. Such a number 
ensured the convergence of the probabilistic 
daily dose, based on the respective summary 
of product characteristics (SPC), and the ex-
factory price or that from the transparency 
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case of treatments available on the market in 
various packages, the unit price was calcu-
lated by weighing the cost of the individual 
products according to their relevant market 
shares [20]. In order to calculate the daily 
cost of insulin in monotherapy or in combina-
tion with oral antidiabetic agents, an average 
requirement of 20 IU/day for basal insulin 
and 50 IU/day for basal-bolus regimens was 
assumed. The use of basal insulin was esti-
mated at 100% in the case of combinations 
with sulphonylureas, GLP-1 and DPP-4, at 
75% when associated with repaglinide, and 
at 38% in combination with metformin [17].
Based on the assumptions hereby defined, 
the cost of the standard treatment was 1.20 
€/day. In line with the EMPA-REG OUT-
COME study design, it was assumed that 
the treatment with empagliflozin was added 
to the standard treatment, resulting in a to-
tal cost for the empagliflozin + SoC arm of 
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pagliflozin add-on is conservative in the per-
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it seems unlikely that in the clinical practice 
empagliflozin could simply be added with-
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concomitance with the base case, an alterna-
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with the previous budget impact analysis [6], 
it was assumed that the adoption of empa-
gliflozin occurred as a replacement of an oral 
antidiabetic agent, except for patients under 
treatment with metformin, insulin and insulin 
associated with metformin. In this scenario, 
the cost of the drug in the empagliflozin + 
SoC arm was 1.86 €/day.
Hospitalization costs for cardiovascular and 
renal events (Table III) were derived from 
the Italian Hospital Tariff System for acute 
diseases, weighed for the relative hospital-
ization frequencies [21,22]. For cardiovascu-
lar death, it was assumed that – on average 
– only half of the cases are hospitalized. The 
cost of renal replacement therapy was esti-
mated at € 41,027, corresponding to the cost 
of kidney dialysis per patient per year [23]. 
Finally, it was assumed that, for the manage-
ment of macroalbuminuria and kidney injury, 
there is no need for hospitalization, but out-
patient services are sufficient.
sensitivity analysis and scenarios
Cost-effectiveness analysis results were es-
timated for the base case and for an explor-
atory scenario. The latter concerned the cost 
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3,897.89 DRG 121 – CV disorders with acute MI, CV complications, discharged alive
DRG 122 – CV disorders with acute MI, without CV complications, discharged alive
[21,22]
Non-fatal stroke 6,073.00 DRG 559 – Acute ischemic stroke with use of thrombolytic agent [21]
Heart failure 3,052.00 DRG 127 – Heart failure and shock [21]
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8,080.55 DRG 547 – Coronary bypass with cardiac catheter with major CV diagnosis
DRG 549 – Coronary bypass without cardiac catheter with major CV diagnosis
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diagnosis
DRG 555 – Percutaneous CV procedures with major CV diagnosis
DRG 557 – Percutaneous CV procedures with drug-eluting stent with major CV 
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[21,22]
Macroalbuminuria 22.26 1 Creatinine test (90.16.4 creatinine clearance)
1 Nephrological visit (89.7 GP visit)
[21]
Kidney injury1 42.92 1 Creatinine test (90.16.4 creatinine clearance)
1 Nephrological visit (89.7 GP visit)
1 Nutritional visit (89.7 GP visit)
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Kidney failure2 41,027.00 Annual cost for dialysis [23]
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death
2,009.00 DRG 123 – CV disorders with acute MI (assumption: 50% of sudden deaths/ not 
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[21]
Table III. Hospitalization costs for cardiovascular and renal events
1 Doubling of serum creatinine level and eGFR = 45 ml/min/1.73m2
2 Beginning of renal-replacement therapy
CV = cardiovascular; GP = general practitioner; MI = myocardial infarction
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cost for patients treated with empagliflozin + 
SoC. This reduction led to a total cost differ-
ence between the two comparator’s arms of € 
2,162, lowering the ICER to € 2,205/QALY 
(Table V).
sensitivity analysis
The probabilistic sensitivity analysis allows 
to simultaneously analyze the impact of vari-
ous sources of uncertainty. The analysis was 
performed by assigning a statistic probability 
distribution to each parameter of the model, 
so that – at each iteration – the set of input 
values  was slightly different (thus represent-
ing the uncertainty on the parameters). The 
calculation of the results was repeated for 
500 iterations. The results of the PSA were 
graphically analyzed on the cost-effective-
ness plane and as cost-effectiveness accept-
ability curve (CEAC). In the graph of the 500 
iterations of the cost-effectiveness plane, the 
point cloud is sufficiently compact around 
the central value, demonstrating a good sta-
bility of the model data (Figure 2).
The mean value of the ICER resulting from 
the sensitivity analysis (4,791 €/QALY) 
is close to the point value of the base case. 
The ICER credibility range – defined as the 
range in which 95% of the analysis values 
fall – is 3,148-6,503 €/QALY. The CEAC is 
a graphic representation of the likelihood that 
a treatment is cost-effective as a function of 
the threshold value for the cost-effectiveness 
acceptability. The CEAC of the comparison 
empagliflozin + SoC vs SoC shows that em-
pagliflozin has about a 100% probability of 
being cost-effective at acceptability thresh-
olds around 10,000 €/QALY, well below the 
conventionally considered values  (30-50,000 
€/QALY – Figure 3).
dIscussIon
Clinical literature has unequivocally shown 
over the years how T2D can be identified as 
an important risk factor for cardiovascular 
events and how the presence of a cardiovas-
cular disease may extend the impact of T2D 
beyond the mere glycemic control issue. To 
this regard, the EMPA-REG OUTCOME 
study highlighted the possibility of choos-
ing therapeutic strategies that can optimize 
the outcomes of these two intimately related 
chronic situations. The recent results of the 
LEADER study with liraglutide and of the 
SUSTAIN-6 study with semaglutide go in 
the same direction [24,25]. It, therefore, ap-
pears important – for the purpose of a com-
plete technology assessment – to explore in 
depth the relevant aspects of economic effec-
tiveness and sustainability. The first step in 
Increments (empagliflozin + soC vs soC)
Base case scenario1
Life Years 2.0 2.0
QALYs 1.0 1.0
Costs (€) 4,708 2,162
ICER (€/QALY) 4,811 2,205
Table V. Results of the cost-effectiveness analysis in the exploratory scenario
ICER: Incremental Cost-Effectiveness Ratio, QALY = quality-adjusted life years; SoC: 
standard of care;
1 Pharmaceutical cost in the empagliflozin + SoC arm was calculated by assuming the 
replacement of other antidiabetic agents, with exception of metformin and insulin
Figure 2. Results of the probabilistic sensitivity analysis (500 iterations)
Figure 3. Cost-effectiveness acceptability curve (CEAC)
WTP = cost-effective thresholds (willingness to pay)
pharmaceutical costs due to the addition of 
empagliflozin (€ 5,509), resulting in a net in-
crease in total cost of € 4,708 (€ 15,679 and € 
10,971 for empagliflozin + SoC and the SoC, 
respectively). Empagliflozin is cost-effective 
compared to the SoC in patients with T2D 
and established cardiovascular disease, with 
a resulting incremental cost-effectiveness ra-
tio (ICER) of 4,811 €/QALY (Table IV). This 
value is clearly below the cost-effectiveness 
thresholds commonly considered acceptable 
(30-50,000 €/QALY).
In the exploratory scenario, it was assumed 
that the use of empagliflozin occurs through 
the replacement of other antidiabetic drugs 
according to the reimbursability limits of the 
current therapeutic plan (no longer as an add-
on to basic therapy, as in the baseline scenar-
io), with a reduction of the pharmaceutical 
gained in the empagliflozin + SoC and in the 
SoC arm, respectively. Cardiovascular and 
renal costs were averagely lower by € 802, 
despite the increase in survival. This reduc-
tion partially compensates the increase in 
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this direction was made by a previous work, 
through which the same authors of this article 
investigated the financial sustainability of the 
adoption of empagliflozin in Italian patients 
with T2D and established cardiovascular 
disease [6]. The conclusions reached by the 
budget impact analysis methodology were 
that empagliflozin can be a viable therapeu-
tic option, both clinically and economically, 
and that the hypothesized use of the same 
treatment could take place without a negative 
budget impact borne by the Italian National 
Health Service [6]. The aim of this study was 
to complete the path with the cost-effective-
ness assessment of the treatment in the same 
setting. The analysis was conducted using 
a patient-level simulation model, directly 
based on the EMPA-REG OUTCOME data. 
The advantage of this type of model is that 
it allows to extrapolate the risk functions of 
cardiovascular and renal events directly from 
the trial data, without the need of surrogate 
outcomes to estimate results and costs over 
the long term. On the other hand, the tight 
relation with the randomized trial constitutes 
the main limitation of the model itself. As in 
all randomized clinical trials, in the EMPA-
REG OUTCOME study, the enrollment was 
governed by the criteria pre-arranged in the 
protocol. In the opinion of the authors of this 
article, this led to the probable exclusion of 
a series of too complex or too frail patients 
who may represent a large component of 
the Italian clinical reality. This limitation is 
typical of randomized clinical trials, which 
measure the effects of treatments in an ex-
perimental setting, often different from clini-
cal reality. Another common problem related 
to the use of efficacy data from clinical trials 
into cost-effectiveness models is related to 
the extrapolation to the long-term frame. In 
our case, the follow-up period of the EMPA-
REG OUTCOME study was relatively long 
(3 years) but in any case, the extrapolation to 
a lifetime horizon is introducing some uncer-
tainty. This was, however, partially addressed 
in the probabilistic sensitivity analysis where 
all parameters of the risk equations were 
varied within their uncertainty ranges. A sec-
ond major limitation of the study is linked to 
the use of utilities for the estimation of the 
quality of life which are not derived from an 
Italian study. This limit is, according to the 
personal experience of the Authors, unfor-
tunately quite common in cost-effectiveness 
analyses in the Italian setting, due to the poor 
production of original quality of life studies. 
Another limitation of the analysis is inher-
ently linked to the use of cost data available 
in the literature and, in some cases, based on 
DRG rates, instead of real costs. The results 
cost for patients treated with empagliflozin + 
SoC. This reduction led to a total cost differ-
ence between the two comparator’s arms of € 
2,162, lowering the ICER to € 2,205/QALY 
(Table V).
sensitivity analysis
The probabilistic sensitivity analysis allows 
to simultaneously analyze the impact of vari-
ous sources of uncertainty. The analysis was 
performed by assigning a statistic probability 
distribution to each parameter of the model, 
so that – at each iteration – the set of input 
values  was slightly different (thus represent-
ing the uncertainty on the parameters). The 
calculation of the results was repeated for 
500 iterations. The results of the PSA were 
graphically analyzed on the cost-effective-
ness plane and as cost-effectiveness accept-
ability curve (CEAC). In the graph of the 500 
iterations of the cost-effectiveness plane, the 
point cloud is sufficiently compact around 
the central value, demonstrating a good sta-
bility of the model data (Figure 2).
The mean value of the ICER resulting from 
the sensitivity analysis (4,791 €/QALY) 
is close to the point value of the base case. 
The ICER credibility range – defined as the 
range in which 95% of the analysis values 
fall – is 3,148-6,503 €/QALY. The CEAC is 
a graphic representation of the likelihood that 
a treatment is cost-effective as a function of 
the threshold value for the cost-effectiveness 
acceptability. The CEAC of the comparison 
empagliflozin + SoC vs SoC shows that em-
pagliflozin has about a 100% probability of 
being cost-effective at acceptability thresh-
olds around 10,000 €/QALY, well below the 
conventionally considered values  (30-50,000 
€/QALY – Figure 3).
dIscussIon
Clinical literature has unequivocally shown 
over the years how T2D can be identified as 
an important risk factor for cardiovascular 
events and how the presence of a cardiovas-
cular disease may extend the impact of T2D 
beyond the mere glycemic control issue. To 
this regard, the EMPA-REG OUTCOME 
study highlighted the possibility of choos-
ing therapeutic strategies that can optimize 
the outcomes of these two intimately related 
chronic situations. The recent results of the 
LEADER study with liraglutide and of the 
SUSTAIN-6 study with semaglutide go in 
the same direction [24,25]. It, therefore, ap-
pears important – for the purpose of a com-
plete technology assessment – to explore in 
depth the relevant aspects of economic effec-
tiveness and sustainability. The first step in 
Increments (empagliflozin + soC vs soC)
Base case scenario1
Life Years 2.0 2.0
QALYs 1.0 1.0
Costs (€) 4,708 2,162
ICER (€/QALY) 4,811 2,205
Table V. Results of the cost-effectiveness analysis in the exploratory scenario
ICER: Incremental Cost-Effectiveness Ratio, QALY = quality-adjusted life years; SoC: 
standard of care;
1 Pharmaceutical cost in the empagliflozin + SoC arm was calculated by assuming the 
replacement of other antidiabetic agents, with exception of metformin and insulin
Figure 2. Results of the probabilistic sensitivity analysis (500 iterations)
Figure 3. Cost-effectiveness acceptability curve (CEAC)
WTP = cost-effective thresholds (willingness to pay)
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rates over time under standard of care alone 
and with empagliflozin in addition to the 
standard of care therapy (Table IA).
steps for determining predictors 
and parametric distribution
A systematic two-stage analytical process 
was used to develop event-free survival func-
tions for the clinical events included in the 
model.
1. Population-level time-to-event surviv-
al curves were fit to the EMPA-REG 
OUTCOME trial data considering var-
ious potential statistical distributions. 
Empirical time-to-event curves were 
derived using the Kaplan-Meier method 
to ascertain the shape of the distribution 
in each treatment arm. Extrapolation of 
time-to-event distributions beyond the tri-
al timeframe was handled with paramet-
ric survival analyses methods. Statistical 
distributions (i.e., exponential, Weibull, 
log-Normal, log-Logistic, Gompertz) 
that can account for the typically skewed 
distributions of time-to-event variables 
were considered in the fitting process. 
The process of selecting the best fitting 
distribution involved both statistical and 
clinical considerations, including good-
ness of fit (Akaike’s Information Crite-
ria and Bayesian Information Criterion), 
plausibility of results, and parsimony 
(preference for the simplest functional 
form). The approach to fitting the curves 
was as outlined in Ishak et al. [28], which 
provides the technical details behind the 
steps of the analyses. Results of this anal-
ysis provide the parameters (i.e., shape, 
scale) for the baseline distribution of each 
KM curve for each arm (base overall 
curve). Survival analyses were performed 
in SAS version 9.4.
2. A Cox proportional-hazards analysis 
was conducted to develop individual 
patient-level risk equations based on 
patient characteristics and event histo-
ry. Baseline and time-dependent predic-
tors that impact the risk of the outcome 
event were tested for significance in the 
risk equations. Candidate characteris-
tics for predictors were selected based 
on clinical relevance as indicated in pre-
specified analysis for the trial endpoints, 
and included treatment arm (pooled em-
pagliflozin doses versus placebo), demo-
graphic information (age, sex, geographic 
region), baseline biomarkers (HbA1c, 
BMI, eGFR), baseline event history (car-
diovascular, cerebrovascular, and periph-
eral arterial disease), and cardiovascular 
and renal events experienced during trial 
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of the study showed that patients treated with 
empagliflozin lived on average two years 
more than patients with standard treatment, 
due to the lower incidence of cardiovascular 
events and mortality. The higher cost, due to 
the addition of empagliflozin, seems fairly 
compensated by the benefit on the outcomes, 
with an ICER of 4,811 €/QALY, a value 
which is significantly lower than the cost-
effectiveness thresholds most commonly 
considered acceptable (30-50,000 €/QALY). 
Also in the sensitivity analysis, which takes 
into account the uncertainty of all the input 
data of the study, the upper limit of the 95% 
confidence interval (3,148-6,503 €/QALY) 
was far from the thresholds, thus showing the 
reliability of the conclusions produced by the 
model. It could be interesting to note that the 
ICER obtained in this study is generally low-
er than those reported in other important ther-
apeutic areas in Italy. Consider, for example, 
the cost-effectiveness analysis of a biologi-
cal product for the treatment of rheumatoid 
arthritis (ICER = 17,100 €/QALY [26]), or 
that of a tyrosine-kinase inhibitor (TKI) au-
thorized for the treatment of chronic myeloid 
leukemia (ICER = 22,529 €/QALY [27]). 
It is, therefore, reasonable to consider reas-
suring the cost-effectiveness results of em-
pagliflozin in the treatment of subjects with 
T2D and established cardiovascular disease, 
even within the discussed limitations of the 
study. Empagliflozin, therefore, represents an 
efficient investment in terms of allocation of 
the Italian NHS’s resources, since it ensures 
a lower additional cost per QALY than other 
biotechnological treatments. All this consid-
ered, and in concomitance with the results of 
the budget impact analysis [6], we can, there-
fore, conclude that empagliflozin can be a 
valid therapeutic option in subjects with T2D 
and established cardiovascular disease, both 
from a clinical and economic perspective.
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appendIx a
Time dependent parametric survival analy-
ses of the EMPA-REG OUTCOME trial data 
were conducted to characterize clinical event 
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rates over time under standard of care alone 
and with empagliflozin in addition to the 
standard of care therapy (Table IA).
steps for determining predictors 
and parametric distribution
A systematic two-stage analytical process 
was used to develop event-free survival func-
tions for the clinical events included in the 
model.
1. Population-level time-to-event surviv-
al curves were fit to the EMPA-REG 
OUTCOME trial data considering var-
ious potential statistical distributions. 
Empirical time-to-event curves were 
derived using the Kaplan-Meier method 
to ascertain the shape of the distribution 
in each treatment arm. Extrapolation of 
time-to-event distributions beyond the tri-
al timeframe was handled with paramet-
ric survival analyses methods. Statistical 
distributions (i.e., exponential, Weibull, 
log-Normal, log-Logistic, Gompertz) 
that can account for the typically skewed 
distributions of time-to-event variables 
were considered in the fitting process. 
The process of selecting the best fitting 
distribution involved both statistical and 
clinical considerations, including good-
ness of fit (Akaike’s Information Crite-
ria and Bayesian Information Criterion), 
plausibility of results, and parsimony 
(preference for the simplest functional 
form). The approach to fitting the curves 
was as outlined in Ishak et al. [28], which 
provides the technical details behind the 
steps of the analyses. Results of this anal-
ysis provide the parameters (i.e., shape, 
scale) for the baseline distribution of each 
KM curve for each arm (base overall 
curve). Survival analyses were performed 
in SAS version 9.4.
2. A Cox proportional-hazards analysis 
was conducted to develop individual 
patient-level risk equations based on 
patient characteristics and event histo-
ry. Baseline and time-dependent predic-
tors that impact the risk of the outcome 
event were tested for significance in the 
risk equations. Candidate characteris-
tics for predictors were selected based 
on clinical relevance as indicated in pre-
specified analysis for the trial endpoints, 
and included treatment arm (pooled em-
pagliflozin doses versus placebo), demo-
graphic information (age, sex, geographic 
region), baseline biomarkers (HbA1c, 
BMI, eGFR), baseline event history (car-
diovascular, cerebrovascular, and periph-
eral arterial disease), and cardiovascular 
and renal events experienced during trial 
P
ar
am
et
er
E
st
im
at
e 
o
f 
C
o
ef
fic
ie
nt
C
lin
ic
al
 E
ve
nt
n
o
n-
fa
ta
l M
I
n
o
n-
fa
ta
l s
tr
o
ke
U
A
h
F
TI
A
R
ev
as
cu
la
ri
za
tio
n
C
V
 D
ea
th
M
ac
ro
al
b
um
in
ur
ia
R
en
al
 in
ju
ry
R
en
al
 f
ai
lu
re
S
ta
tis
tic
al
 D
is
tri
bu
tio
n
E
xp
on
en
tia
l
W
ei
bu
ll
E
xp
on
en
tia
l
W
ei
bu
ll
E
xp
on
en
tia
l
E
xp
on
en
tia
l
W
ei
bu
ll
G
om
pe
rtz
E
xp
on
en
tia
l
E
xp
on
en
tia
l
S
ha
pe
1.
00
0
0.
92
6
1.
00
0
0.
99
7
1.
00
0
1.
00
0
1.
15
5
0.
21
4
1.
00
0
1.
00
0
Lo
g(
sc
al
e)
5.
31
0
6.
12
5
5.
28
0
7.
54
9
8.
18
4
3.
96
7
5.
66
8
-3
.7
11
5.
70
5
7.
39
9
C
o
ef
fic
ie
nt
s
A
ge
 (y
ea
rs
)
0.
01
2
0.
01
6
0.
03
1
0.
04
5
0.
02
2
Fe
m
al
e
-0
.2
50
-0
.1
77
-0
.1
95
B
M
I ≥
30
 k
g/
m
2
-0
.2
30
0.
49
0
0.
23
1
-0
.0
79
H
bA
1c
 ≥
8.
5%
0.
36
4
0.
27
8
H
is
to
ry
 o
f n
on
-fa
ta
l s
tro
ke
0.
72
5
-0
.3
11
0.
53
1
-0
.5
92
0.
47
7
0.
25
0
H
is
to
ry
 o
f n
on
-fa
ta
l M
I
0.
66
7
0.
26
9
0.
50
6
0.
57
8
H
is
to
ry
 o
f C
A
B
G
0.
19
7
0.
41
4
-0
.3
64
-0
.2
96
0.
20
3
H
is
to
ry
 o
f M
C
A
D
0.
56
8
0.
73
7
0.
51
7
H
is
to
ry
 o
f S
VC
A
D
H
is
to
ry
 o
f P
A
D
0.
42
8
-0
.3
04
0.
48
6
0.
18
8
0.
29
0
0.
40
8
1.
10
5
eG
FR
 <
60
 m
l/m
in
/1
.7
3m
2
0.
12
0
0.
17
5
0.
45
2
0.
30
4
0.
70
9
0.
64
2
0.
92
4
eG
FR
 6
0-
90
 m
l/m
in
/1
.7
3m
2
-0
.2
71
0.
33
0
0.
21
7
0.
08
1
0.
03
5
0.
23
4
-0
.1
74
R
eg
io
n,
 A
fri
ca
0.
22
0
-0
.6
29
0.
14
7
0.
45
7
-0
.2
24
-0
.3
99
0.
06
0
0.
96
0
R
eg
io
n,
 A
si
a
-0
.5
30
-0
.1
48
-0
.3
09
-0
.2
54
-1
.4
67
-0
.5
54
0.
39
3
R
eg
io
n,
 E
ur
op
e
-0
.1
53
-0
.1
67
-0
.2
08
-0
.1
82
-0
.7
73
-0
.2
67
0.
24
3
R
eg
io
n,
 L
at
in
 A
m
er
ic
a
-0
.3
06
-0
.9
74
0.
09
8
-0
.6
55
-2
.1
76
-0
.2
49
0.
19
2
E
m
pa
gl
ifl
oz
in
 T
x
-0
.1
38
0.
25
6
0.
02
7
-0
.3
70
-0
.1
56
-0
.0
60
-0
.3
63
-0
.4
71
-0
.4
72
-0
.5
09
N
on
-fa
ta
l M
I
1.
07
7
0.
70
3
1.
27
7
3.
11
8
1.
28
2
1.
31
4
N
on
-fa
ta
l s
tro
ke
0.
84
4
0.
65
6
U
A
0.
65
7
0.
77
4
2.
78
1
H
F
1.
13
4
0.
59
9
1.
36
6
2.
84
6
TI
A
1.
70
7
1.
09
9
R
ev
as
cu
la
riz
at
io
n
0.
88
0
M
ac
ro
al
bu
m
in
ur
ia
0.
41
5
1.
23
0
0.
96
8
1.
70
4
R
en
al
 in
ju
ry
1.
36
2
0.
78
7
0.
38
8
1.
27
6
R
en
al
 fa
ilu
re
Ta
b
le
 IA
. R
is
k 
eq
ua
tio
ns
 p
re
di
ct
in
g 
tim
e 
to
 c
lin
ic
al
 e
ve
nt
s
B
M
I =
 b
od
y 
m
as
s 
in
de
x;
 C
A
B
G
 =
 c
or
on
ar
y 
ar
te
ry
 b
yp
as
s 
gr
af
tin
g;
 e
G
FR
 =
 e
st
im
at
ed
 g
lo
m
er
ul
ar
 fi
ltr
at
io
n 
ra
te
; H
F 
=
 h
ea
rt 
fa
ilu
re
; M
C
A
D
 =
 m
ul
ti-
ve
ss
el
 c
or
on
ar
y 
ar
te
ry
 d
is
ea
se
; M
I =
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 P
A
D
 =
 p
er
ip
he
ra
l a
rte
ry
 d
is
ea
se
; 
S
VC
A
D
 =
 s
in
gl
e 
ve
ss
el
 c
or
on
ar
y 
ar
te
ry
 d
is
ea
se
; T
IA
 =
 tr
an
si
en
t i
sc
he
m
ic
 a
tta
ck
; T
x 
=
 tr
ea
tm
en
t; 
U
A
 =
 u
ns
ta
bl
e 
an
gi
na
52 Farmeconomia. Health economics and therapeutic pathways 2017; 18(1)
Cost-effectiveness analysis of empagliflozin in the treatment of patients with T2D and established cardiovascular disease in Italy
references
1. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular 
disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22; https://doi.org/10.1016/
S0140-6736(10)60484-9
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. 
JAMA 2002; 287: 2570-81; https://doi.org/10.1001/jama.287.19.2570
3. World Heart Federation. Diabetes. Available at: http://www.world-heart-federation.org/cardiovascular-health/
cardiovascular-disease-risk-factors/diabetes/ (last accessed May 2017)
4. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Out-
comes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-28; https://doi.org/10.1056/NEJMoa1504720
5. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression 
of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-34; https://doi.org/10.1056/NEJMoa1515920
6. Iannazzo S, Maggioni AP, Mannucci E. Analisi di impatto sul budget di empagliflozin nel trattamento dei pazienti 
con diabete di tipo 2 e malattia cardiovascolare accertata. GRHTA 2017; 4: e122-32
7. Kansal A, Zheng Y, Proskorovsky I, et al. Long-term Economic Outcomes of Empagliflozin (Jardiance) Treatment 
in Type 2 Diabetes Mellitus (T2DM) based on the EMPA-REG OUTCOME Trial. American Diabetes Association 
76th Scientific Sessions, June 10-14, 2016. New Orleans, LA, USA
8. Gibbons I, Kandaswamy P, Tebboth A, et al. Cost-effectiveness of empagliflozin (Jardiance) in the treatment of 
patients with Type 2 Diabetes Mellitus (T2DM) in the UK based on EMPA-REG OUTCOME data. ISPOR 19th 
Annual European Congress. October 2016, Vienna, Austria
9. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression 
of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-34; https://doi.org/10.1056/NEJMoa1515920
10. ISTAT. Tavole di mortalità della popolazione residente. Anno: 2015. Available at: http://demo.istat.it (last accessed 
March 2017)
11. Lombardo F, Spila Alegiani S, Maggini M, et al., on behalf of Studio DAI. Istituto Superiore di Sanità. Prevalenza 
e incidenza delle complicanze del diabete: studio DAI. Rapporti ISTISAN 07/25, 2017
12. AMD Associazione Medici Diabetologi. Annali AMD 2012
13. Szende A, Janssen B, Cabases J (Eds). Self-Reported Population Health: An International Perspective based on 
EQ-5D. Springer, 2014
14. Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 
2011; 31: 800-4; https://doi.org/10.1177/0272989X11401031
15. Sullivan PW, Ghushchyan VH. EQ-5D Scores for Diabetes-Related Comorbidities. Value Health 2016; 19: 1002-8; 
https://doi.org/10.1016/j.jval.2016.05.018
16. Lindgren P, Graff J, Olsson AG, et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose 
simvastatin. Eur Heart J 2007; 28: 1448-53; https://doi.org/10.1093/eurheartj/ehm020
17. QuintilesIMS, Patient Analyzer MAT Marzo 2016. Data on file
18. CODIFA – L’Informatore Farmaceutico. Available at: http://www.codifa.it/ (last accessed May 2017)
19. Agenzia Italiana del Farmaco (AIFA). Lista di trasparenza degli equivalenti aggiornata ad aprile 2016. Available at: 
http://www.agenziafarmaco.gov.it/it/content/liste-di-trasparenza-e-rimborsabilit%C3%A0 (last accessed May 2017)
tivariate equations contain predictors 
that have a significant effect or impor-
tant prognostic factors that show a non-
negligible effect size. The Cox regression 
analysis provided tables of hazard ratios 
for covariates included in each equation 
that are used to adjust the base curves. 
Time-dependent multivariate parametric 
survival regression models were built us-
ing R version 3.2.2.
follow-up. The predictor selection strate-
gy involved first assessing each potential 
predictor for significance (p < 0.2) in uni-
variate analysis to determine whether it is 
associated with the outcome on its own. 
The significant predictors were combined 
in multivariate parametric equations, 
trimmed one variable at a time (in order 
of highest p-value) to exclude variables 
not significant at p < 0.2. The final mul-
53Farmeconomia. Health economics and therapeutic pathways 2017; 18(1)
S. Iannazzo, E. Mannucci, O. Reifsnider, A. P. Maggioni
20. QuintilesIMS. Dati di mercato Sell-in SU FisYr/12/2015 (Absolute). Data on file
21. Ministero della Salute. DECRETO 18 ottobre 2012. Remunerazione prestazioni di assistenza ospedaliera per acuti, 
assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. 
GU n.23 del 28-1-2013 - Suppl. Ordinario n. 8
22. Ministero della Salute. Ricoveri ospedalieri (SDO). Dati 2014. Available at: http://www.salute.gov.it/portale/temi/
p2_4.jsp?area=ricoveriOspedalieri (last accessed April 2017)
23. Censis (Centro Studi Investimenti Sociali) - SIN (Società Italiana di Nefrologia) - Centro Nazionale Trapianti. 
Il valore del trapianto – Sintesi dei Risultati, 17 dicembre 2013. Available at: http://www.censis.it (last accessed 
March 2017)
24. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee.; LEADER Trial Investigators. 
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-22; https://doi.
org/10.1056/NEJMoa1603827
25. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in 
Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844; https://doi.org/10.1056/NEJMoa1607141
26. Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment 
of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ 2012; 15: 576-85; https://doi.org/10.3111/136969
98.2012.665110
27. Lucioni C, Iannazzo S, Mazzi S, et al. Valutazione di costo-efficacia di ponatinib nella terapia della leucemia mie-
loide cronica in Italia. GRHTA 2015; 2: 1-16
28. Ishak KJ, Kreif N, Benedict A, et al. Overview of parametric survival analysis for health-economic applications. 
Pharmacoeconomics 2013; 31: 663-75; https://doi.org/10.1007/s40273-013-0064-3
